Rigel Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Rigel Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 14, 2026, to be held virtually.
NASDAQ
Rigel Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Rigel Pharmaceuticals is asking stockholders to approve an amendment to its 2018 Equity Incentive Plan to increase the number of shares available for issuance by 700,000.
NASDAQ
Rigel Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Rigel Pharmaceuticals is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.